Cladribine, Idarubicin, Cytarabine, and Venetoclax Trial
Phase 2
508
about 16 years
18–65
1 site in TX
What this study is about
This trial is testing a treatment with cladribine, idarubicin, cytarabine, and venetoclax for people with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blastic phase chronic myeloid leukemia. The goal of this treatment is to stop the growth of cancer cells.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Laboratory Biomarker Analysis
- 2.Take Cladribine
- 3.Take Cytarabine
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
cladribine, cytarabine, gilteritinib, idarubicin, midostaurin, venetoclax
injection, intravenous, injection (Injection), oral (Oral Tablet), oral (Oral Capsule), oral
Primary: Complete response (CR) rate
Secondary: Duration of response, Event-free survival (EFS), Incidence of toxicities, Overall response rate (ORR), Overall survival (OS)
Oncology, Musculoskeletal